Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

21. Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness

Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness | CADTH.ca Find the information you need Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Ivabradine for Adults with Stable Chronic Heart Failure: A Review of Clinical Effectiveness Last updated: May 15, 2019 Project Number: RC1119-000 Product Line: Research Type: Drug (...) Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of ivabradine for patients with stable chronic heart failure and with left ventricular ejection fraction > 35% and 40%? Key Message There were no studies identified with inclusion criteria of patients with stable chronic heart failure and left ventricular ejection fraction greater than 35% and less than or equal to 40% Two studies, however, included patients with LVEF less than 40% and were

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

22. Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines

Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness (...) , and Guidelines Natriuretic Peptide Testing for Monitoring of Heart Failure Therapy: A Review of Clinical Effectiveness, Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 19, 2019 Project Number: RC1163-000 Product Line: Research Type: Devices and Systems Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and clinical utility of natriuretic peptide testing for the monitoring of heart failure therapy? What is the cost

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

23. Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness

Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness | CADTH.ca Find the information you need Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments (...) : Clinical Utility and Cost-Effectiveness Point of Care Ultrasound for Assessment of Patients with Suspected or Known Chronic Heart Failure in Emergency Departments: Clinical Utility and Cost-Effectiveness Last updated: August 27, 2019 Project Number: RB1380-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of point of care ultrasound for the assessment of patients with suspected or known chronic heart failure

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

24. Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory

. -,NO. -,2019 Hollenberg et al. -,2019:-–- Heart Failure Hospitalization Pathway 9TABLE 4 Key Comorbid Conditions to Consider Comorbidity Management Relevant Guidelines/Pathways Cardiovascular Coronary artery disease/acute coronary syndrome Assess and treat ischemia, and consider revascularization. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction Atrial ?brillation/ ?utter (...) Patients Hospitalized with Heart Failure: Risk Assessment, Management, and Clinical Trajectory EXPERT CONSENSUS DECISION PATHWAY 2019 ACC Expert Consensus Decision PathwayonRiskAssessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure A Report of the American College of Cardiology Solution Set Oversight Committee Writing Committee Steven M. Hollenberg, MD, FACC, Chair Lynne Warner Stevenson, MD, FACC, Vice Chair Tariq Ahmad, MD, MPH, FACC Vaibhav J. Amin, MD

2019 American College of Cardiology

25. Cardiac rehabilitation for heart failure can improve quality of life and fitness. (Abstract)

Cardiac rehabilitation for heart failure can improve quality of life and fitness. The studyTaylor RS, Walker S, Ciani O, et al. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis. Health Technol Assess 2019;23:1-98.This project was funded by the NIHR Health Technology Assessment Programme (project number 15/80/30).To read the full NIHR Signal, go to https://discover.dc.nihr.ac.uk/content/signal-000803/cardiac (...) -rehabilitation-for-heart-failure-can-improve-quality-of-life-and-fitness.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

2019 BMJ

26. The Effect of Renal Denervation on Exercise Tolerance in Patients with Heart Failure

criteria were appraised with the GRADE system for quality. Results: Three studies were considered after the exclusion criteria were applied. The first study assessing RDN for patients with heart failure was terminated early due to low recruitment. Another study by the same group showed that RDN was a promising treatment needing more research and clinical evidence. The most recent study, an RCT, found that RDN safely improved cardiac function and exercise tolerance in patients with heart failure (...) The Effect of Renal Denervation on Exercise Tolerance in Patients with Heart Failure "The Effect of Renal Denervation on Exercise Tolerance in Patients with" by Meredith Dahle < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Heart Failure is a growing clinical syndrome that results in major impacts on patients and the medical system. Previously, therapy has

2019 Pacific University EBM Capstone Project

27. Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure

Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure 1 Translation of the key statement of the final report N16-02 Telemonitoring mithilfe von aktiven kardialen implantierbaren Aggregaten bei ventrikulärer Tachyarrhythmie sowie Herzinsuffizienz (Version 1.2; Status: 4 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. N16-02 Telemonitoring using active cardiac implantable devices in ventricular tachyarrhythmia and heart failure 1 Extract of final report N16-02 Version 1.2 Telemonitoring using active cardiac implantable devices 4 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Telemonitoring using

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

28. Ivabradine (Lancora) for Heart Failure

Ivabradine (Lancora) for Heart Failure Ivabradine (Lancora) for Heart Failure | CADTH.ca Find the information you need Ivabradine (Lancora) for Heart Failure Ivabradine (Lancora) for Heart Failure Last updated: August 8, 2019 Project Number: HO0006-000 Product Line: Technology Review Result type: Report Heart failure is a condition characterized by reduced cardiac output occurring due to complications of cardiovascular disease. It is a leading cause of hospital admissions and has a poor

2019 CADTH - Technology Review

29. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. (Abstract)

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. In patients with type 2 diabetes, inhibitors of sodium-glucose cotransporter 2 (SGLT2) reduce the risk of a first hospitalization for heart failure, possibly through glucose-independent mechanisms. More data are needed regarding the effects of SGLT2 inhibitors in patients with established heart failure and a reduced ejection fraction, regardless of the presence or absence of type 2 diabetes.In this phase 3, placebo (...) -controlled trial, we randomly assigned 4744 patients with New York Heart Association class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either dapagliflozin (at a dose of 10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or cardiovascular death.Over a median of 18.2 months, the primary outcome occurred

2019 NEJM

30. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. Full Text available with Trip Pro

Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. In patients with heart failure and reduced ejection fraction (HFrEF), treatment with sacubitril-valsartan reduces N-terminal pro-b-type natriuretic peptide (NT-proBNP) concentrations. The effect of sacubitril-valsartan on cardiac remodeling is uncertain.To determine whether NT (...) -proBNP changes in patients with HFrEF treated with sacubitril-valsartan correlate with changes in measures of cardiac volume and function.Prospective, 12-month, single-group, open-label study of patients with HFrEF enrolled in 78 outpatient sites in the United States. Sacubitril-valsartan was initiated and the dose adjusted. Enrollment commenced on October 25, 2016, and follow-up was completed on October 22, 2018.NT-proBNP concentrations among patients treated with sacubitril-valsartan.The primary

2019 JAMA

31. Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Full Text available with Trip Pro

Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. Compared with enalapril, sacubitril-valsartan reduces cardiovascular mortality and heart failure hospitalization in patients with heart failure and reduced ejection fraction (HFrEF). These benefits may be related to effects on hemodynamics and cardiac remodeling.To determine whether treatment of HFrEF with sacubitril-valsartan improves (...) central aortic stiffness and cardiac remodeling compared with enalapril.Randomized, double-blind clinical trial of 464 participants with heart failure and ejection fraction of 40% or less enrolled across 85 US sites between August 17, 2016, and June 28, 2018. Follow-up was completed on January 26, 2019.Randomization (1:1) to sacubitril-valsartan (n = 231; target dosage, 97/103 mg twice daily) vs enalapril (n = 233; target dosage, 10 mg twice daily) for 12 weeks.The primary outcome was change from

2019 JAMA Controlled trial quality: predicted high

32. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. Full Text available with Trip Pro

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The angiotensin receptor-neprilysin inhibitor sacubitril-valsartan led to a reduced risk of hospitalization for heart failure or death from cardiovascular causes among patients with heart failure and reduced ejection fraction. The effect of angiotensin receptor-neprilysin inhibition in patients with heart failure with preserved ejection fraction is unclear.We randomly assigned 4822 patients with New York Heart (...) Association (NYHA) class II to IV heart failure, ejection fraction of 45% or higher, elevated level of natriuretic peptides, and structural heart disease to receive sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily) or valsartan (target dose, 160 mg twice daily). The primary outcome was a composite of total hospitalizations for heart failure and death from cardiovascular causes. Primary outcome components, secondary outcomes (including NYHA class change, worsening

2019 NEJM Controlled trial quality: predicted high

33. Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting

Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting Hand-held ultrasound devices - Health Technology Wales > Hand-held ultrasound devices Hand-held ultrasound devices Topic Status Complete Hand-held ultrasound devices for cardiac assessment and diagnosis of heart failure, in the community or primary care setting. Outcome of the appraisal Hand-held ultrasound devices (HUDs) show promise in the diagnosis of heart failure (...) was this topic appraised? Heart failure is a common and serious condition that is exerting an increasing burden on cardiology and heart imaging services in Wales. The diagnosis of heart failure can be suspected from clinical assessment and biochemical testing but the use of cardiac ultrasound (echocardiography) is pivotal to either confirming or excluding the diagnosis. Echocardiography is usually done in a hospital setting, but the use of hand-held ultrasound devices means that it can be offered as a quick

2019 Health Technology Wales

34. Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease Full Text available with Trip Pro

Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease Patients with chronic coronary artery disease or peripheral artery disease and history of heart failure (HF) are at high risk for major adverse cardiovascular events. We explored the effects of rivaroxaban with or without aspirin in these patients.The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) randomized 27 395 participants with chronic (...) coronary artery disease or peripheral artery disease to rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily, rivaroxaban 5 mg twice daily alone, or aspirin 100 mg alone. Patients with New York Heart Association functional class III or IV HF or left ventricular ejection fraction (EF) <30% were excluded. The primary major adverse cardiovascular events outcome comprised cardiovascular death, stroke, or myocardial infarction, and the primary safety outcome was major bleeding using modified

2019 EvidenceUpdates

35. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. Full Text available with Trip Pro

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study. To investigate the cardiovascular effectiveness of sodium glucose cotransporter 2 (SGLT2) inhibitors in routine clinical practice.Cohort study using data from nationwide registers and an active-comparator new-user design.Denmark, Norway, and Sweden, from April 2013 to December 2016.20 983 new users of SGLT2 inhibitors and 20 983 new users (...) of dipeptidyl peptidase 4 (DPP4) inhibitors, aged 35-84, matched by age, sex, history of major cardiovascular disease, and propensity score.Primary outcomes were major cardiovascular events (composite of myocardial infarction, stroke, and cardiovascular death) and heart failure (hospital admission for heart failure or death due to heart failure). Secondary outcomes were the individual components of the cardiovascular composite and any cause death. In the primary analyses, patients were defined as exposed

2019 BMJ

36. Effects of Serelaxin in Patients with Acute Heart Failure. Full Text available with Trip Pro

Effects of Serelaxin in Patients with Acute Heart Failure. Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to cardiovascular and renal adaptations during pregnancy. Previous studies have suggested that treatment with serelaxin may result in relief of symptoms and in better outcomes in patients with acute heart failure.In this multicenter, double-blind, placebo-controlled, event-driven trial, we enrolled patients who were hospitalized for acute heart (...) and worsening heart failure at 5 days.A total of 6545 patients were included in the intention-to-treat analysis. At day 180, death from cardiovascular causes had occurred in 285 of the 3274 patients (8.7%) in the serelaxin group and in 290 of the 3271 patients (8.9%) in the placebo group (hazard ratio, 0.98; 95% confidence interval [CI], 0.83 to 1.15; P = 0.77). At day 5, worsening heart failure had occurred in 227 patients (6.9%) in the serelaxin group and in 252 (7.7%) in the placebo group (hazard ratio

2019 NEJM Controlled trial quality: predicted high

37. Planning to reduce 30-day adverse events after discharge of frail elderly patients with acute heart failure: design and rationale for the DEED FRAIL-AHF trial. (Abstract)

Planning to reduce 30-day adverse events after discharge of frail elderly patients with acute heart failure: design and rationale for the DEED FRAIL-AHF trial. To demonstrate the efficacy of a system for comprehensive care transfer (Multilevel Guided Discharge Plan [MGDP]) for frail older patients diagnosed with acute heart failure (AHF) and to validate the results of MGDP implementation under real clinical conditions. The MGDP seeks to reduce the number of adverse outcomes within 30 days

2019 Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias Controlled trial quality: uncertain

38. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction Full Text available with Trip Pro

Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction Angiotensin-converting enzyme (ACE) inhibitors are beneficial in heart failure with reduced ejection fraction (HFrEF). We sought to describe longitudinal trends in estimated glomerular filtration rate (eGFR) in HFrEF and how ACE-inhibitor therapy influences these changes.Post hoc analysis of trial data.Symptomatic (Treatment Trial, n=2,423) and asymptomatic (Prevention

2019 EvidenceUpdates

39. Cardiac contractility modulation device implantation for heart failure

Cardiac contractility modulation device implantation for heart failure Cardiac contr Cardiac contractility modulation de actility modulation device vice implantation for heart failure implantation for heart failure Interventional procedures guidance Published: 26 June 2019 www.nice.org.uk/guidance/ipg655 Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) tissues. It can lead to oedema in the lungs (causing breathlessness) and swelling of the legs. Other symptoms include reduced ability to exercise, fatigue and malaise. Heart failure can be caused by structural or functional abnormalities of the heart. Current treatments 2.2 NICE's guideline describes the diagnosis and management of chronic heart failure in adults. Treatments for heart failure include drugs to improve heart function, cardiac rehabilitation, cardiac resynchronisation therapy and cardiac

2019 National Institute for Health and Clinical Excellence - Interventional Procedures

40. Analysis of How Emergency Physicians' Decisions to Hospitalize or Discharge Patients With Acute Heart Failure Match the Clinical Risk Categories of the MEESSI-AHF Scale (Abstract)

Analysis of How Emergency Physicians' Decisions to Hospitalize or Discharge Patients With Acute Heart Failure Match the Clinical Risk Categories of the MEESSI-AHF Scale The Multiple Estimation of Risk Based on the Emergency Department Spanish Score in Patients With Acute Heart Failure (MEESSI-AHF) is a validated clinical decision tool that characterizes risk of mortality in emergency department (ED) acute heart failure patients. The objective of this study is to compare the distribution of risk (...) categories between hospitalized and discharged ED patients with acute heart failure.We included consecutive acute heart failure patients from 34 Spanish EDs. Patients were retrospectively classified according to MEESSI-AHF risk categories. We calculated the odds of hospitalization (versus direct discharge from the ED) across MEESSI-AHF risk categories. Next, we assessed the following 30-day postdischarge outcomes: ED revisit, hospitalization, death, and their combination. We used Cox hazards models

2019 EvidenceUpdates